Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The miR-205 response elements on ZEB2 mRNA are specific regulatory sequences located within the 3' untranslated region (3' UTR) of the ZEB2 (Zinc Finger E-Box Binding Homeobox 2) transcript. These elements serve as the physical binding sites for the microRNA miR-205, which post-transcriptionally silences ZEB2 expression through mechanisms of mRNA degradation or translational inhibition. ZEB2 is a critical transcription factor that drives the epithelial-mesenchymal transition (EMT), a cellular program that enables epithelial cells to acquire invasive mesenchymal properties, facilitating cancer metastasis. In many aggressive cancers, such as breast, prostate, and renal cell carcinoma, miR-205 is significantly downregulated, leading to the pathological upregulation of ZEB2 and the subsequent loss of epithelial markers like E-cadherin. Therapeutic strategies targeting these response elements include the delivery of miR-205 mimics to restore ZEB2 repression and inhibit tumor progression, as well as the use of target site blockers (TSBs) designed to specifically modulate the miR-205/ZEB2 interaction. Furthermore, the miR-205/ZEB2 axis is implicated in therapy resistance, where restoring miR-205 function can sensitize cancer cells to radiation and chemotherapy.
miR-205 mimics bind to these response elements to induce ZEB2 mRNA degradation or translational repression, thereby inhibiting EMT and promoting MET. Target site blockers (TSBs) are antisense oligonucleotides that bind to these specific elements to prevent miR-205 from interacting with ZEB2 mRNA, which can be used to study the axis or potentially treat conditions where miR-205-mediated repression is undesirable.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on miR-205 response elements on Zinc Finger E-Box Binding Homeobox 2 (ZEB2) mRNA.